

Resource Summary Report

Generated by [RRID](#) on Aug 7, 2026

Phospho-HER2/ErbB2 (Tyr1221/1222) Antibody

RRID:AB_2099241

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2249, RRID:AB_2099241

Antibody Information

URL: http://antibodyregistry.org/AB_2099241

Proper Citation: Cell Signaling Technology Cat# 2249, RRID:AB_2099241

Target Antigen: Phospho-HER2/ErbB2 (Tyr1221/1222)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W

Antibody Name: Phospho-HER2/ErbB2 (Tyr1221/1222) Antibody

Description: This polyclonal targets Phospho-HER2/ErbB2 (Tyr1221/1222)

Target Organism: h, human

Antibody ID: AB_2099241

Vendor: Cell Signaling Technology

Catalog Number: 2249

Record Creation Time: 20250820T010619+0000

Record Last Update: 20250820T100239+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-HER2/ErbB2 (Tyr1221/1222) Antibody.

No alerts have been found for Phospho-HER2/ErbB2 (Tyr1221/1222) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Trenker R, et al. (2024) Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation. eLife, 12.

Marrocco I, et al. (2023) L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. Cell reports. Medicine, 4(8), 101142.

Mukherjee R, et al. (2021) Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Molecular cell, 81(4), 708.

Feng WW, et al. (2019) CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies. Cell reports, 29(11), 3405.

Pahuja KB, et al. (2018) Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer cell, 34(5), 792.